Balance Sheet

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Sunshine Biopharma (SBFM) Gains from Investment Securities (2016 - 2024)

Sunshine Biopharma filings provide 4 years of Gains from Investment Securities readings, the most recent being -$373529.0 for Q4 2024.

On a quarterly basis, Gains from Investment Securities changed N/A to -$373529.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$373529.0, a 139.07% decrease, with the full-year FY2024 number at $582483.0, changed N/A from a year prior.
Gains from Investment Securities hit -$373529.0 in Q4 2024 for Sunshine Biopharma, down from $956012.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $956012.0 in Q1 2024 to a low of -$373529.0 in Q4 2024.